1 July 2025 in European Respiratory Review
Bronchiectasis is a chronic respiratory disease characterised by irreversible bronchial dilation, persistent productive cough and alternating periods of clinical stability and exacerbations. The distorted airways impair mucus clearance, making them susceptible to recurrent infections and chronic inflammation. Haemophilus influenzae is a common pathogen in bronchiectasis according to international registries. It employs several virulence mechanisms, including adhesion, intracellular invasion/survival, biofilm formation and evasion of antibiotic treatments, to establish infection. These mechanisms allow H. influenzae to persist in the respiratory tract and evade host immune defences. Although its role is well-documented in other airway diseases, the impact of H. influenzae in bronchiectasis remains incompletely understood. International guidelines do not recommend eradication therapy for H. influenzae upon first isolation, while this intervention is advised for Pseudomonas aeruginosa in such cases. Long-term immunomodulatory treatment with macrolides is an option for patients with bronchiectasis with chronic H. influenzae infection and frequent exacerbations, though it carries the risk of promoting antibiotic resistance and a Pseudomonas-enriched airway microbiome. Studies indicate significant negative interactions between P. aeruginosa and H. influenzae, suggesting a competitive relationship that can influence microbiome dynamics and potentially affect clinical outcomes. Currently, there is insufficient evidence to support vaccination against nontypeable H. influenzae in chronic airways disease. Despite its frequent detection in respiratory samples, the precise role of H. influenzae in bronchiectasis-related morbidity and disease progression is not fully understood and warrants further investigation. This review examines the impact of H. influenzae on bronchiectasis pathophysiology and progression, comparing its role in other chronic respiratory diseases.
27 February 2025 in ERJ Open Research
Bronchiectasis and chronic rhinosinusitis are chronic diseases of the upper and lower respiratory tract characterised by both infective and inflammatory pathways. The two share many clinical, radiological, microbiological and pathophysiological aspects. Bronchiectasis and chronic rhinosinusitis may be characterised by different endotypes, with inflammation driven by either neutrophils and/or eosinophils. Although the two conditions may coexist, the prevalence of their association remains uncertain. To date, few studies have investigated the pathogenetic relationship between these disorders, with ambiguous results obtained in heterogeneous populations. Some findings suggest that patients with both chronic rhinosinusitis and bronchiectasis may have a heavier disease burden consisting of more exacerbations, more debilitating symptoms, higher radiological severity and worse quality of life. In light of this, identification of treatable traits is crucial and patients are likely to benefit from a multidisciplinary approach involving, among others, pulmonologists, ear-nose-throat physicians, respiratory physiotherapists and allergists/immunologists.
31 July 2025 in ERJ Open Research
Bronchiectasis is a heterogeneous chronic respiratory disease characterised by permanent bronchial dilation, daily productive cough and frequent exacerbations [1]. In recent years, the understanding of bronchiectasis has evolved beyond the paradigm of recurrent infections and structural lung damage. Systemic inflammation and coexisting comorbidities are now recognised as integral components of disease pathophysiology [2–4]. Moreover, patients increasingly emphasise the need for personalised and flexible management strategies, pointing out the limitations of a one-size-fits-all approach [5].
30 October 2025 in ERJ Open Research
Bronchiectasis is a chronic respiratory disease characterised by permanent bronchial dilatation associated with chronic productive cough and recurrent respiratory infections [1]. The European Respiratory Society (ERS) guidelines recommend etiological screening at the time of bronchiectasis diagnosis to identify treatable causes or those that may influence disease management [2]. Data from EMBARC, the European bronchiectasis registry, suggest an association between bronchiectasis and rheumatoid arthritis (RA) in up to 2.7% of cases, while other connective tissue diseases (CTDs) are present in up to 2.1% of cases [3].
11 December 2025 in ERJ Open Research
Bronchiectasis is a chronic respiratory condition characterised by irreversible bronchial dilatation, persistent respiratory symptoms and recurrent exacerbations [1]. Despite significant progress in understanding its pathophysiology, many diagnostic and therapeutic decisions remain based on expert opinion [2, 3]. In particular, the role of bronchoscopy remains debated. According to current guidelines, bronchoscopy should be considered in patients with nonproductive cough and signs of infection on computed tomography (CT), or when obstructive causes or nontuberculous mycobacterial pulmonary disease (NTM-PD) are suspected [2, 3].
1 September 2026 in ERJ Open Research
Extract We would like to thank L. Nguyen-Ho and Q-K. Tran-Le for their insightful comments on our study regarding the clinical impact of bronchoscopy in bronchiectasis management [1]. Their highlights regarding the potential role of bronchial lavage (BL) in inflammatory endotyping beyond microbiology are both timely and highly relevant. Shareable abstract Think bronchoscopy is just for samples? Think again. It impacts clinical management in >50% of bronchiectasis cases with a high safety profile: moving from expert opinion to data-driven care. https://bit.ly/3NYVAM3